CompanyGraph
Globus Medical Inc.
GMED · NYSE Arca · United States
Sells spinal implants and a surgical robot that legally lock surgeons into using them together.
Globus Medical sells titanium and cobalt-chromium spinal implants paired with its Excelsius surgical robot, but each implant-robot combination requires its own FDA 510(k) clearance before surgeons can legally use it in the operating room. Those clearances depend on clinical data generated through hands-on cadaveric training at Globus's Audubon facility, so the physical laboratory — its floor space and its cadaver supply — is the actual bottleneck controlling how fast new procedure types can be approved and sold. Because a surgeon's Excelsius certification does not transfer to any competing robot, and because hospitals have wired the robot's navigation software into their own imaging systems, switching would mean retraining staff from scratch under a different clearance framework entirely. The whole structure depends on Audubon continuing to operate: if cadaver procurement dries up or the facility loses its ISO 13485 certification, new clearances stop, the platform cannot expand into additional procedures, and the lock-in stops compounding.
How does this company make money?
The company earns money each time a hospital buys a spinal implant or a set of surgical instruments. It also sells the Excelsius robot itself as a large upfront capital purchase. After that sale, hospitals continue paying for software licenses and maintenance contracts on the robot, creating a recurring stream of income on top of the initial equipment sale.
What makes this company hard to replace?
Surgeons who trained on Excelsius cannot apply that training to a different robot — the certification does not transfer, and they would have to go through a completely separate training process. Hospitals that installed Excelsius have also connected its navigation software to their existing imaging systems, and unwinding that integration is time-consuming and expensive. On top of that, FDA clearances are tied to specific implant-robot pairings, so a hospital cannot simply swap in a competitor's implants and keep using the Excelsius robot legally.
What limits this company?
The Audubon cadaveric lab can only train so many surgeons at a time, and it can only work with as many cadavers as it can procure. That physical ceiling determines how fast clinical data piles up, which in turn determines how many new 510(k) applications can be submitted. The FDA clearance clock cannot run faster than the lab does.
What does this company depend on?
The company cannot run without titanium and cobalt-chromium alloys from specialized metals suppliers, FDA 510(k) clearances for each Excelsius robotic procedure type, ISO 13485 certification for its manufacturing facilities, surgeons willing to complete hands-on training at the Musculoskeletal Education and Research Center cadaveric labs, and hospital capital equipment budgets large enough to purchase Excelsius platform installations.
Who depends on this company?
Spine surgeons rely on the Excelsius platform for robotic navigation during complex fusion procedures — without it, they lose that precision guidance entirely. Orthopedic trauma centers depend on the company for rapid production of custom implants in emergency cases. Teaching hospitals use the Audubon cadaveric labs to train resident surgeons in spine procedures, and that training pipeline would stop if the facility closed.
How does this company scale?
Standard implant shapes can be produced in larger volumes by adding more clean room space and CNC machining centers — that part of the business can grow without reinventing anything. But surgeon training cannot be done online or at a distance; it requires physical lab space and actual cadavers at the Audubon facility. As the company tries to expand into more procedure types, that lab remains the fixed chokepoint.
What external forces can significantly affect this company?
If Medicare lowers its reimbursement rates for spinal fusion procedures, hospitals will perform fewer of them, which directly reduces demand for implants and Excelsius use. Titanium prices can spike when the aerospace industry competes for the same metal, pushing up the cost of every implant. In Europe, the company faces the European Medical Device Regulation, which requires a separate and more demanding body of clinical evidence before products can be sold there.
Where is this company structurally vulnerable?
If cadaver supply to the Audubon facility dried up — because of a change in state anatomical gift laws, a broken supply agreement, or a compliance failure that cost the facility its ISO 13485 certification — no new clinical data could be generated. Without that data, no new 510(k) applications could go forward. The Excelsius platform would be frozen at its current set of approved procedures, surgeon adoption would slow, and the lock-in that keeps hospitals from switching to competitors would stop growing.